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ABSTRACT
Platelet inhibition has been considered an effective strategy for combating 
cancer metastasis and compromising disease malignancy although recent clinical 
data provided evidence that long-term platelet inhibition might increase incidence of 
cancer deaths in initially cancer-free patients. In the present study we demonstrated 
that dual anti-platelet therapy based on aspirin and clopidogrel (ASA+Cl), a routine 
regiment in cardiovascular patients, when given to cancer-bearing mice injected 
orthotopically with 4T1 breast cancer cells, promoted progression of the disease 
and reduced mice survival in association with induction of vascular mimicry (VM) in 
primary tumour. In contrast, treatment with ASA+Cl or platelet depletion did reduce 
pulmonary metastasis in mice, if 4T1 cells were injected intravenously. In conclusion, 
distinct platelet-dependent mechanisms inhibited by ASA+Cl treatment promoted 
cancer malignancy and VM in the presence of primary tumour and afforded protection 
against pulmonary metastasis in the absence of primary tumour. In view of our data, 
long-term inhibition of platelet function by dual anti-platelet therapy (ASA+Cl) might 
pose a hazard when applied to a patient with undiagnosed and untreated malignant 
cancer prone to undergo VM.
INTRODUCTION
Platelets contribute to tumour cell growth as well 
as metastatic spread [1]. An increase in platelet number 
inversely correlates with cancer patient survival [2]. 
Furthermore, defective platelet function or reduced platelet 
count is associated with decreased metastasis [3–5]. Given 
the possible role of platelets in promotion of malignant 
diseases and metastatic spread, effects of anti-platelet 
therapy on metastasis have been intensively studied 
in animal models [3, 6, 7] as well as in humans. Today 
there is overwhelming evidence from epidemiological 
studies [8–12] and clinical trials [13, 14] that supports the 
involvement of platelets in metastatic spread.
Aspirin, inhibiting cyclooxygenase-1 (COX-1) –
derived thromboxane A2 (TXA2) synthesis in platelets (and 
thus platelet aggregation and degranulation) was the first 
anti-platelet drug used to combat cancer metastasis [15]. 
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There are a number of reports in experimentally introduced 
tumours and in clinical trials that demonstrate cancer-
preventive [16–19] and anti-metastatic effects of aspirin 
[10, 20], although the latter effect was not consistent 
in all studies [2]. In cardiovascular patients, aspirin is 
frequently administered together with thienopyridines 
(for example clopidogrel) that antagonize P2Y12 receptors 
and prevent ADP-induced platelet activation. Surprisingly, 
recent clinical data suggest that long-term treatment with 
clopidogrel and other thienopyridines could increase 
the number of non-cardiovascular deaths, half of them 
were attributed to cancer [9, 14]. Moreover, inhibition 
of thrombin generation by vorapaxar applied on top of 
conventional anti-platelet therapy based on combination of 
aspirin and clopidogrel was also associated with increased 
cancer incidence in initially cancer-free cardiovascular 
patients [21]. Finally, it has been recently reported that 
some anticoagulants (warfarin) [22] or, surprisingly, 
platelet depletion [23] could increase metastatic burden 
in mice. Accordingly, in contrast with the numerous 
pre-clinical studies that have repeatedly shown slower 
progression of malignant diseases upon treatment with 
anti-platelet agents, recent evidence suggests that platelet 
inhibition with clopidogrel or vorapaxar might accelerate 
cancer progression in patients. In fact, the emerging 
controversy regarding the beneficial vs detrimental 
effects of platelet inhibition on progression of cancer has 
recently been documented in clinical trials [9, 14, 21]. 
Hence, we tested a hypothesis that platelet inhibition 
with aspirin and clopidogrel has differential effects on 
the primary tumour, as opposed to metastatic spread. We 
investigated the effects of dual anti-platelet therapy based 
on aspirin and clopidogrel on primary tumour growth in 
the murine model of 4T1 breast cancer after orthotopic 
injection of 4T1 breast cancer cells in comparison to the 
effects of aspirin and clopidogrel treatment on pulmonary 
metastasis after intravenous injection of 4T1 breast cancer 
cells. Our results clearly demonstrate differential effects 
of platelet inhibition with aspirin and clopidogrel on 
primary breast cancer growth and pulmonary metastasis. 
We demonstrated that platelet-dependent mechanisms 
inhibited by dual anti-platelet treatment with aspirin and 
clopidogrel promoted cancer malignancy and VM in 
the presence of primary tumour and afforded protection 
against pulmonary metastasis in the absence of primary 
tumour.
RESULTS
Effects of aspirin and clopidogrel on mice 
survival in the orthotopic model of metastatic 
4T1 breast cancer
Survival of tumour-bearing mice receiving dual anti-
platelet therapy based on aspirin (ASA) and clopidogrel 
(Cl) (4T1+ASA/Cl group, n=40) was diminished as 
compared with control tumour-bearing mice not subjected 
to the ASA+Cl treatment (4T1 control group, n=80) 
(P=0.0259) (Figure 1). Concomitantly, in ASA+Cl-treated 
mice, lung expression of negative prognostic factors 
of malignancy such as transforming growth factor β1 
(TGFβ1), cyclooxygenase-2 (COX-2) and prostacyclin 
synthase (PGI2S) (41-43), was higher, despite the lower 
level of tissue remodeling/angiogenesis markers such 
as metaloproteinases/vascular endothelial growth factor 
A (VEGFA) (Supplementary Figure 1). Interestingly, 
there was no difference in body mass, primary tumour 
weight, primary tumour volume, lung weight, number of 
Figure 1: Effects of dual anti-platelet therapy with aspirin and clopidogrel on mice survival after orthotopic injection 
of 4T1 cells. Mice were injected orthotopically with 1x104 of 4T1 cells (n=120). Once the primary tumour was palpable, the designated 
group of animals started to receive aspirin (ASA) and clopidogrel (Cl) with the chow diet (12 mg +12 mg per kg of body weight per 
day) (dotted line; 4T1+ASA/Cl mice, n=40) whereas others continued on the standard chow (solid line; 4T1 mice, n=80). The disease 
progression was monitored throughout the experiment, and the number of days survived was registered for each animal until both groups 
were euthanized terminally in the 5th week of the disease. Survival curves of both groups were compared with the generalised Wilcoxon 
(Peto-Prentice) test. The symbol * indicates statistical significance at P<0.05.
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pulmonary metastases, relative pulmonary metastatic area 
and WBC count between 4T1+ASA/Cl and 4T1 control 
mice (Table 1). However, the number of circulating 
platelets was higher in 4T1+ASA/Cl mice, and correlated 
with a higher number of megakaryocytes in the spleen. 
Systemic NO bioavailability was also higher in 4T1+ASA/
Cl mice, as evidenced by higher plasma NO2
-, NO3
-
concentrations and higher HbNO levels in blood (Table 1).
Effects of aspirin and clopidogrel on pro-
thrombotic phenotype of platelets in the 
orthotopic model of metastatic 4T1 breast cancer
To confirm effectiveness of dual anti-platelet 
ASA+Cl therapy, basal and ADP-induced platelet 
reactivity (Figure 2A-2D), ex vivo thromboxane B2 (TXB2) 
generation (Figure 2E) and platelet aggregates formation 
(Figure 2F) were measured. As shown in Figure 2A-2D, 
anti-platelet therapy in 4T1+ASA/Cl group attenuated 
ADP-induced increase in platelet P-selectin (n=7-5, 
P<0.05), vWF (n=8, P<0.001) and fibrinogen binding 
(n=8, P<0.001) on the platelet surface when compared 
with ADP-stimulated platelets in 4T1 control mice. Anti-
platelet treatment inhibited also ex vivo TXB2 generation in 
4T1+ASA/Cl group when compared with not treated 4T1 
control mice (471.4 vs 219.6 pg·ml·106PLT for control 
and ASA-Cl mice, respectively, n=7-12, P=0.0010 in 
basal conditions as well as after 60 minutes of mechanical 
stimulation (stirring): 10024 vs 1017.0 pg·ml·106 PLT 
for control and ASA-Cl-treated mice, respectively, n=7-
12, P=0.0015) (Figure 2E). Effectiveness of platelet 
inhibition by ASA-Cl treatment was also confirmed by 
decreased tendency of platelets to form aggregates in 
the circulation when compared to control 4T1 mice: no 
difference between control 4T1 and 4T1+ASA/Cl groups 
was observed with respect to the number of smaller 
objects <2.5 μm, but the number and size of larger platelet 
aggregates > 10 μm were significantly lower in ASA-Cl-
treated mice (Figure 2F).
Effects of aspirin and clopidogrel on 
development of vascular mimicry in the primary 
tumour in orthotopic model of metastatic 4T1 
breast cancer
In 4T1+ASA/Cl group, the number of PAS-positive 
and CD31-negative pseudovessels in primary tumours was 
higher compared to control 4T1 mice (69310±35033 pixels 
for 4T1 mice vs 139608±58524 pixels for 4T1+ASA/Cl 
mice, n=9-10, P=0.005) (Figure 3A-3F), compatible with 
vascular mimicry (VM) in the primary tumours induced 
by ASA+Cl treatment, with no difference in the number 
of PAS-positive and CD31-positive endothelium-lined 
vessels (Figure 3A-3D and 3G). These results indicated a 
higher number of pseudovessels in ASA+Cl-treated mice 
without any difference in the number of blood vessels 
between ASA+Cl-treated and control 4T1 mice. Induction 
of VM in primary tumours of 4T1+ASA/Cl mice was 
confirmed by higher expression of VE-cadherin (VE-
CAD) and secretory leukocyte protease inhibitor (Slpi) 
(Figure 3H) with no change in MMP-9, all reported to be 
markers of VM [24, 22, 25, 26]. Blood vessels in primary 
tumours of 4T1+ASA/Cl group were dysfunctional, as 
evidenced by low expression of the endothelial isoform 
of nitric oxide synthase (eNOS) and higher expression 
of Angiopoetin-2 (Ang-2) (Figure 3H). Induction of VM 
by ASA+Cl treatment was associated with lower relative 
necrotic area in the primary tumours of mice receiving 
the ASA+Cl anti-platelet therapy (0.65±0.1 for 4T1 mice 
vs 0.56±0.09 for 4T1+ASA/Cl mice, n=18-20, P=0.006) 
(Figure 4A-4E).
Effects of aspirin and clopidogrel on pro-
angiogenic phenotype of platelets in the 
orthotopic metastatic 4T1 breast cancer in mice
Pro-angiogenic phenotype of platelets decreases 
with platelet age, since senescence of platelets is 
associated with their loss of function and smaller size 
[27, 28]. Therefore, “young” platelets contain more 
proangiogenic proteins and are bigger in size, whereas 
for “old” platelets the opposite is observed. As shown 
in Figure 5A, platelet phenotype in 4T1+ASA/Cl mice 
was more pro-angiogenic, since they contained more 
proangiogenic VEGFA and PDGF AB +BB and less 
antiangiogenic TSP-1, PF4/CXCL4 and TGFβ1 when 
compared with platelets isolated from control 4T1 mice. 
Moreover, despite the similar number of smaller “old” 
platelets in the circulation of 4T1+ASA/Cl mice and 
control 4T1 mice, the number of large “young” platelets in 
4T1+ASA/Cl mice was higher compared with control 4T1 
mice (Figure 5B), indicating thrombopoesis in response to 
platelet inhibition with ASA+Cl.
Effects of aspirin and clopidogrel or platelet-
depleting antibody on pulmonary metastasis 
after intravenous injection of 4T1 breast cancer 
cells
To investigate whether anti-platelet therapy with 
ASA+Cl would decrease pulmonary metastasis in the 
absence of primary tumour, mice were injected i.v. with 
ASA+Cl and then with 4T1-ln2-tdTomato cells. As 
shown in Figure 6A and 6B, combination of ASA and 
Cl decreased pulmonary metastases after i.v. injection of 
4T1-ln2-tdTomato cells (assessed as lung fluorescence 
intensity: 165±118 a.u. in control 4T1 mice vs 70±61 
in 4T1+ASA/Cl mice, n=8-14, P=0.0342 by bootstrap-
boosted unpaired Student’s t test). Similarly, depletion 
of platelets with antibody inhibited metastasis after i.v. 
injection of 4T1 cells (the difference in lung weight: 
3.7; 3.4-4.1% of body mass of control 4T1 mice vs 2.7; 
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1.7-3.6% of body mass of 4T1+Ab mice, n=7, P=0.017, 
and the number of lung metastases in control 4T1 mice 
440.0;322.0-477.0 vs 263.0; 145.0-308.0 for 4T1+Ab 
mice, n=7, P=0.002, Figure 6C and 6D). Lower number 
of pulmonary metastases after platelet depletion was also 
associated with improved systemic endothelial function 
in 4T1+Ab mice, as evidenced by higher production of 
NO in aorta of 4T1+Ab group as compared with 4T1 mice 
(Supplementary Figure 2).
DISCUSSION
In the present work, we demonstrated that dual 
antiplatelet therapy with aspirin and clopidogrel (ASA+Cl) 
given to 4T1 breast cancer-bearing mice after orthotopic 
inoculation of cancer cells effectively inhibited ADP-and 
TXB2-dependent responses in platelets, inhibited pro-
thrombotic phenotype of platelets (Figure 2) but stimulated 
vascular mimicry (VM) in the primary tumour (Figure 3), 
Table 1: Effects of dual anti-platelet therapy with aspirin and clopidogrel on cancer progression, blood cell count 




Body mass-primary tumour [g] 19.6±1.8 (n=53) 18.9±1.7 (n=17)
Primary tumour weight [g] 2.00±1.03 (n=68) 2.07±0.08 (n=26)
Primary tumour volume [mm3] 1205.0±419.4 (n=60) 1145.0±455.0 (n=40)
Lung weight [% body weight] 1.9±0.8 (n=49) 2.0±0.9 (n=26)
Number of metastases on the lungs’ 
surface 60; 55.0-75 (n=14) 62; 36-82 (n=9)
Number of metastases on H&E-
stained lung cross-sections 59; 51-90 (n=10) 84; 38-109 (n=8)
Area of pulmonary metastases [% 
of lung cross-section area] 29.3±9.6% (n=10) 20.7±10.9% (n=8)
WBC [K · μl-1] 249.7±151.0 (n=36) 293.8±102.2 (n=8)
GRA [K · μl-1] 152.4±95.2 (n=34) 182.7±54.8 (n=8)
LYM [K · μl-1] 63.4±51.3 (n=35) 71.9±29.8 (n=8)
PLT [K · μl-1] 907.5±191.3 (n=56) 1026.0±161.3 (n=16)* (P=0.022)
Number of megakaryocytes per 
eyefield in the spleen 12.7; 11.0-14.5 (n=13) 15.4; 13.0-17.0 (n=9)
* (P=0.048)
HbNO [AU per mg] 371.4±157.7 (n=23) 532.0±199.7 (n= 9) (P=0.024)*
NO2
- [μM] 0.36±0.1 (n=22) 0.84±0.50 (n=10) (P=0.003)**
NO3
- [μM] 14.7±5.7 (n=23) 20.1±6.2 (n=10) (P=0.022)*
Data are presented as mean ± SD or median and IQR. Body mass and primary tumour volume of mice injected with 1×104 
4T1 cells (4T1) and those injected with 4T1 cells and receiving dual anti-platelet therapy (4T1+ASA/Cl) were monitored 
throughout the experiment. Mice were euthanized in the 5th week of the disease, the blood cell count was performed and the 
lungs were excised for further analysis of pulmonary metastasis; primary tumours were excised and weighed. Pulmonary 
metastasis was assessed by counting the number of secondary nodules on formalin-fixed lung lobe surfaces under a 
magnifying glass. Subsequently, the lobes were paraffin-embedded, cut into slices and stained with H&E. The slices were 
scanned with a BX51 microscope equipped with virtual microscopy system dotSlide (Olympus, Japan), and the number of 
pulmonary metastases was counted concomitantly with the total area of pulmonary metastasis expressed as the percentage 
of lung cross-section area. Spleens were excised, weighed and fixed in formaldehyde, paraffin-embedded, cut into slices 
and stained with H&E. The slices were photographed and the number of megakariocytes was counted, as described in 
Materials and Methods. Systemic NO bioavailability was assessed by measurement of HbNO adducts in RBC as well as 
plasma NO2
- and NO3
- concentrations. The data were analyzed with two-sided Student T test or the non-parametric Mann-
Whitney U test depending on the variable scale, the normality of distribution and the variance homogeneity (F test). The 
symbols * and ** indicate statistical significance at, respectively, P<0.05 and P<0.01.
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Figure 2: Effects of dual anti-platelet therapy with aspirin and clopidogrel on pro-thrombotic phenotype of platelets 
in orthotopic metastatic breast cancer model. In the case of (A-D), results are presented as median of data without outliers; n=7-8 
for control 4T1 mice (light grey), n=5-8 for ASA+Cl-treated 4T1 mice (dark grey), in the case of (E) results are presented as median of 
data without outliers; n=12 for control 4T1 mice and n=7-8 for ASA+Cl-treated 4T1 mice, in the case of (F) as mean + SD or median and 
IQR; n=7 for control 4T1 mice and n = 7 for ASA+Cl-treated 4T1 mice. Mice were randomly assigned to control not-treated group (4T1; 
light grey) or the group that received anti-platelet therapy (4T1+ASA-Cl; dark grey). Platelet activation and their ADP-induced reactivity 
were assessed by exposure of their surface antigens P-selectin (A), active form of the receptor GPIIb/IIIa (B), von Willebrandt factor (vWF) 
binding, (C) and fibrinogen binding (D) to visualize the effectiveness of clopidogrel treatment. Based on the normality of distribution 
and variance homogeneity (Barlett’s test), the medians in (A-C) were compared with Kruskal-Wallis test followed by Dunn’s multiple 
comparison test; data shown in (D) were analysed with Two-Way ANOVA followed by Bonferroni post-hoc multiple comparisons test, the 
data of TXB2 (E) were analysed with Mann-Whitney U test to visualize effectiveness of aspirin treatment. (F) The sizes of CD61/CD41-
positive objects in subpopulations of normoplatelets (cluster 1) and aggregates (cluster 2) in control (light grey) and ASA+Cl-treated (dark 
grey) 4T1 mice were assessed to confirm that platelet inhibition was associated with decreased formation of aggregates in the circulation 
of 4T1+ASA/Cl mice. Objects were discriminated based on flow cytometry forward scatter data, with the use of the Data Mining-assisted 
generalized cluster analysis by EM (expectation-maximization) algorithm decomposing the overall population into two exponentially-
modified Gaussian partial distributions relevant to platelet subpopulations representing small objects (normoplatelets, predominantly single 
blood platelets, subpopulation 1) and larger objects (platelet aggregates with other blood cells, subpopulation 2) in 4T1 and ASA+CL-
treated 4T1 mice. The contributions of normoplatelets and aggregates were 83.8% and 16.2% in 4T1 controls vs. 86.0% vs. 14.0% in 4T1 
mice treated with ASA+CL (P< 0.0001 for aggregates: 16.2; 15.1-18.3% in control vs. 14.0; 13.3-14.8% in 4T1+ASA/Cl mice, by the 
bootstrap-boosted estimate of the one-sided Mann-Whitney U test, 1000 iterations). The symbols ** and *** indicate statistical significance 
at, respectively, P<0.01 and P<0.001.
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resulting in accelerated progression of the disease and 
decreased mice survival (Figure 1). In contrast, in mice 
with 4T1 cells injected intravenously and, thus, without 
a primary tumour, inhibition of platelets with ASA+Cl or 
platelet depletion with anti-platelet antibody significantly 
reduced pulmonary metastasis (Figure 6). Our results 
demonstrate for the first time, that platelet-dependent 
mechanisms inhibited by dual antiplatelet therapy with 
Figure 3: Effects of dual anti-platelet therapy with aspirin and clopidogrel on VM in the primary tumour in orthotopic 
metastatic breast cancer model. Data are presented as mean of data without outliers (F); n =10 for control 4T1 mice, n=9 for 
ASA+Cl-treated 4T1 mice and (G) as median of data without outliers; n=11 for control 4T1 mice and n=9 for ASA+Cl-treated 4T1 
mice. Primary tumours of 4T1 and 4T1+ASA/Cl mice were cut into slices and stained to visualize basement membranes (Periodic Acid 
Schiff staining, PAS) and endothelium-lined blood vessels (CD31). Subsequently, ten randomly chosen eyefields near the regions of 
hypoxia were photographed for each mouse and subjected to segmentation using Ilastik software to assess the number of PAS+/CD31- 
pseudovessels and PAS+/CD31+ endothelium-lined vessels, as described in Materials and Methods. The representative photographs of 
VM in primary tumours of 4T1 and 4T1+ASA/Cl groups are given in (A and B) and the results of their segmentation are given in (C and 
D), respectively. For (C and D), green indicates PAS+/CD31- pseudovessels and red indicates PAS+/CD31+ endothelium-lined vessels. 
In, (E) higher magnification of the data presented in (B) is shown with black arrows pointing to the PAS+/CD31- pseudovascular channels 
perfused by RBC. The mean number of pixels indicating pseudovessels (F) and endothelium-lined vessels (G) was counted with the use 
of Image J. The data were analyzed with either two-sided Student t test (F) test or Mann-Whitney U test (G) depending on the normality 
of distribution and variance homogeneity (tested with F test); the symbol ** indicates statistical significance at P<0.01. For determination 
of VM molecular markers, primary tumours were excised, homogenized and individual samples (n=6 form 4T1 and n=5 from 4T1+ASA/
Cl group) were run on polyacrylamide gels (H). Subsequently, they were processed as described in Materials and Methods. Densytometric 
data [OD] normalised to the total protein are presented as median of the data without outliers. Homogeneity of variances and normality of 
densytometric data distribution were confirmed by F and KS normality tests, respectively, and the data were analysed with two-sided two-
sided Student t test. The symbol * indicates statistical significance at P<0.05.
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Figure 4: Effects of dual anti-platelet therapy with aspirin and clopidogrel on necrosis area in the primary tumour in 
orthotopic metastatic breast cancer model. Data in (E) are presented as mean of data without outliers; n=20 for control 4T1 mice 
and n=18 for ASA+Cl-treated mice. Primary tumours of 4T1 and 4T1+ASA/Cl mice were cut into slices and stained with H&E to assess the 
relative necrotic area, as described in Materials and Methods. Subsequently, the total tumour cross-section area was scanned with a BX51 
microscope equipped with virtual microscopy system dotSlide (Olympus, Japan) and subjected to segmentation in Ilastik software to assess 
the relative necrotic area. The representative photographs for primary tumours of 4T1 and 4T1+ASA/Cl groups are given in (A and B), 
and the results of their segmentation are given in (C and D), respectively. For (C and D), red indicates necrotic area while green indicates 
viable tumour tissue. The mean number of pixels representing necrotic and viable tumour tissue ± SD was counted in Image J (E). Based 
on the normality of distribution and variance homogeneity (F test), the data in (E) were analysed with two-sided Student t test. The symbol 
** indicates statistical significance at P<0.01.
Figure 5: Effects of dual anti-platelet therapy with aspirin and clopidogrel on platelet size and pro-angiogenic 
phenotype in orthotopic metastatic breast cancer model. (A) To investigate the angiogenic phenotype of platelets, isolated 
platelets were lysed and pooled together (n≥6) to obtain sufficient protein amount for WB analysis. Equal amounts of pooled samples were 
separated on the SDS-PAGE, transferred and probed for antiangiogenic as well as proangiogenic proteins stored in platelet α-granules: 
antiangiogenic thrombospondin-1 (TSP-1), platelet factor 4 (PF4/CXCL4), transforming growth factor β1 (TGFβ1) and proangiogenic 
vascular endothelial growth factor (VEGF(A)) and platelet-derived growth factor (PDGF AB +BB). The images in (A) present the fold 
change of each protein of interest in 4T1+ASA/Cl group vs control 4T1 group. Equal protein loading was controlled after electrophoresis 
and transfer for all gels and membranes using a stain free-technique, as described in Materials and Methods. (B) Data are presented as mean 
± SD or median and IQR; n= 7 for control 4T1 mice (light grey) and n = 7 for ASA+Cl-treated 4T1 mice (dark grey). The subpopulation of 
normoplatelets presented in Figure 2F was decomposed into two clusters, representing smaller (subpopulation 1) and larger (subpopulation 
2) platelets. Object sizes were estimated from the standard curve assigned with FSC calibration beads (size range of 1 μm to 15 μm). The 
contributions of smaller and larger objects in the population of normoplatelets were 92.9% and 7.1% in 4T1 controls vs. 92.2% vs. 7.8% in 
4T1 treated with ASA+CL (P< 0.003 for larger objects: 7.1; 6.5-7.5% in control vs. 7.8; 6.5-9.3% in 4T1+ASA/Cl mice, bootstrap estimate 
of the one-sided Mann-Whitney U test, 1000 iterations).
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aspirin and clopidogrel promoted cancer malignancy 
and VM in the presence of primary tumour but afforded 
protection against pulmonary metastasis in the absence of 
primary tumour.
For many years, platelet inhibition was considered 
to slow down the progression of cancer [4, 5, 29–31]. 
However, in the last decade evidence has emerged 
suggesting that chronic platelet inhibition could 
paradoxically promote progression of malignant 
diseases in initially cancer-free patients [8, 9, 11, 21]. 
This observation was confirmed by the DAPT clinical 
trial: long-term platelet inhibition by thienopyridines 
treatment, antagonizing P2Y12 receptors such as prasugrel 
or clopidogrel, was associated with statistically significant 
increase in the incidence of new solid cancer cases and 
the ratio of cancer deaths among initially cancer-free 
cardiovascular patients [14]. In view of data presented 
in this study, we postulate that these adverse effects of 
thienopyridines might be related to induction of VM and 
formation of pseudovascular circulation in latent tumours, 
promoting their malignancy.
Vascular mimicry, discovered by [32], is a very 
common phenomenon in various malignant cancers, 
including breast cancer [22, 33, 34], and is always 
Figure 6: Effects of dual platelet inhibition with aspirin and clopidogrel and platelet depletion on pulmonary metastasis 
in intravenous murine breast cancer model. For (A), the results are presented as mean of data without outliers; n=14 for control 4T1 
mice, n=8 for ASA+Cl-treated 4T1 mice, in the case of (C, D) the results are presented as median of data without outliers; n=7 for control 
4T1 and ASA+Cl-treated mice. (A, B) Mice were injected intravenously (i.v.) with 2×105 of 4T1-luc2td-Tomato cells and were randomly 
assigned either to control not-treated group (4T1) or the group that received dual anti-platelet therapy (ASA+Cl) (aspirin and clopidogrel 1/1 
mg · kg-1 of body weight, respectively) (4T1+ASA/Cl) 45 min prior to cancer cell inoculation. Five hours before cancer cell transplantation, 
mice were injected intraperitoneally (i.p.) with 1 mg · kg-1 of LPS. Mice were sacrificed 24 hours after cancer cell transplantation, lungs were 
collected and their fluorescence was analyzed, as described in Materials and Methods. (C, D) Mice were injected with platelet-depleting 
antibody 15 min before 4T1 breast cancer cell injection (4T1+Ab) or did not receive the antibody (4T1). After 13 days they were euthanized, 
their lungs were excised and weighed and lung weight was expressed as the % of body weight. The number of pulmonary metastases was 
counted on the lobe surface under the magnifying glass after dissection of formaldehyde-fixed lungs. Based on the normality of distribution 
and variance homogeneity (F test), the data were analyzed with Mann-Whitney U test. The symbols * and ** indicate statistical significance 
at P<0.05 and P<0.01, respectively.
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associated with increased malignancy of the disease, 
poor patient prognosis and decreased survival [32]. 
Indeed, we demonstrated here that increased mortality 
of mice orthotopically injected with 4T1 breast cancer 
cells receiving dual anti-platelet therapy based on 
aspirin and clopidogrel throughout the progression of the 
disease was associated not only with more pronounced 
VM in their primary tumours (Figures 3A-3F), but also 
with the increase of other negative markers of cancer 
malignancy: TGFβ1, COX-2 and PGI2S levels in the 
lungs (Supplemetary Figure 1) [35–37] as well as with 
an increased systemic NO bioavailability (Table 1) [38], 
which could indicate more pronounced cancer-associated 
immunosuppression in this cancer model since myeloid-
derived suppressor cells (MDSCs) are known to produce 
large quantities of NO in an arginase- dependent way [39]. 
Furthermore, despite effective attenuation of platelet pro-
thrombotic function (Figure 2), dual anti-platelet treatment 
changed the balance of pro/anti-angiogenic phenotype of 
platelets towards more pro -angiogenic (Figure 5A) that 
could be at least partially explained by the stimulation 
of thrombopoesis by aspirin-clopidogrel treatment. Pro 
-angiogenic phenotype of platelets could contribute 
to cancer progression [2] as well as to VM in aspirin-
clopidogrel treated mice orthotopically injected with 4T1 
breast cancer cells.
Apart from the well-known role in coagulation, 
platelets contain a plethora of growth factors that 
safeguard blood vessel integrity and promote survival 
of endothelial cells [40]. We suggest that deficiency 
of platelet-derived growth factors in mice subjected to 
dual anti-platelet therapy with ASA+Cl could contribute 
to dysfunction of the primary tumour microvasculature 
what could drive VM by VEGF/VEGFR1-dependent 
pathway [41, 42] to support tumour perfusion. Indeed, 
the intratumour area of necrosis was smaller in ASA+Cl-
treated mice (Figure 4), suggesting better tumour 
perfusion concomitantly with induction of VM, as 
evidenced by higher number of PAS+CD31- pixels 
(Figure 3A-3F) and higher levels of VE-CAD and Slpi 
considered as molecular markers of VM [22, 25, 26] 
(Figure 3H). Interestingly, the number of endothelium-
lined blood vessels was similar in the primary tumours 
of ASA+Cl-treated and control 4T1 mice (Figure 3A-
3E, 3G-3H) though they were more dysfunctional in 
mice with inhibited platelets, as evidenced by lower 
expression of eNOS (a marker of “healthy” endothelium) 
in the primary tumour. Also Ang-2, known as the 
vascular destabilizing factor, tended to be higher in 
ASA+Cl-treated mice compared to its expression in 
the primary tumours of control 4T1 mice (Figure 3H). 
Altogether, our results demonstrate that in ASA+Cl-
treated mice VM was activated, concomitantly with 
more pronounced microvascular dysfunction in primary 
tumours. These results stay in line with the emerging 
role of platelets in the regulation of microvascular 
integrity that could be of particular importance in the 
microvascular network of primary tumour [43, 44]. In 
fact, induction of thrombocytopenia consistently resulted 
in massive bleeding in and surrounding the tumour, 
without affecting vascular integrity elsewhere [41, 44].
In the present work, the number of secondary nodules 
or the relative area of metastatic foci in lungs was not higher 
in ASA+Cl-treated mice (Table 1). The expression of 
metalloproteinases (MMPs), von Willebrand factor (vWF) 
and pro-angiogenic VEGF and EphA1 was also not higher 
in the lungs of ASA+Cl-treated mice, while endothelium-
protective Slit2/ROBO4-dependent signaling known to 
prevent endothelium permeability in the lungs was activated 
(Supplementary Figure 1). This discrepancy between 
induction of VM in the primary tumour and the lack of 
increased pulmonary metastasis might seem intriguing. It 
was previously shown that the platelet depletion increased 
metastatic spread to the lungs in this model of breast cancer 
[22, 23]. However, if platelet inhibition would lead to more 
efficient intravasation of 4T1 cells in ASA+Cl-treated mice 
due to more pronounced VM in the primary tumour, it could 
be efficiently counterbalanced by aspirin plus clopidogrel 
treatment lowering metastatic capacity of circulating 4T1 
cells (i.e. aspirin inhibited thromboxane A2 generation by 
platelets and 4T1 cells what lowered metastatic capacity 
of the latter [45]). Indeed, if 4T1 cells were injected 
intravenously, both platelet inhibition and platelet depletion 
reduced pulmonary metastasis (Figure 6) similarly, as 
shown previously [22], clearly suggesting that inhibition of 
platelets by aspirin and clopidogrel inhibited extravasation 
and pulmonary metastasis of 4T1 breast cancer cells. These 
data confirm that platelet inhibition indeed decreases 
extravasation but, if the primary tumour is present, these 
beneficial effects can be overridden by induction of VM 
what could lead to more efficient intravasation of cancer 
cells.
Therefore, better understanding of distinct platetet-
dependent mechanisms regulating extravasation and 
intravasation of cancer cells is fundamental for effective 
and safe anti-platelet therapy.
To summarize, we demonstrated for the first time 
that, dual antiplatelet therapy with aspirin and clopidogrel 
promoted cancer malignancy and VM in the presence of 
primary tumour. On the other dual antiplatelet therapy 
with aspirin and clopidogrel afforded protection against 
pulmonary metastasis in the absence of primary tumour. 
Further studies are needed to define the details of platelet-
dependent mechanisms promoting cancer malignancy and 
VM in the presence of primary tumour and those affording 
protection against pulmonary metastasis in the absence 
of primary tumour. Our results suggest that long-term 
platelet inhibition with dual antiplatelet therapy based 
on aspirin and clopidogrel, though affording unequivocal 
cardiovascular benefits, could pose a significant hazard 
when given to a patient with undiagnosed and untreated 




Female Balb/C mice aged 7-11 weeks were used 
for the experiments (Charles River Laboratory, Germany 
or Medical Centre Bialystok, Poland). Throughout the 
experiment, animals were housed 5-6 per cage, in a 
temperature-controlled environment (22–25°C), maintained 
on a 12-hour light/day cycle and given unlimited access to 
food (Zoolab, Krakow, Poland) and water. Animals were 
euthanized by i.p. injection of ketamine and xylazine, 100 
and 10 mg · kg-1, respectively. All experimental procedures 
involving animals were accepted by the First Local 
Ethical Committee on Animal Testing at the Jagiellonian 
University (Krakow, Poland), permit no: 140/2013, the Local 
Ethical Committee on Animal Testing at the Institute of 
Immunology and Experimental Therapy (Wrocław, Poland) 
no: 78/2015, and the Second Local Ethical Committee on 
Animal Testing in the Institute of Pharmacology, Polish 
Academy of Sciences (Krakow, Poland), permit no: 
41/2017. Orthotopic injection: 120 mice were randomly 
divided into control group (80 mice; 4T1) or treated group 
that received combined anti-platelet therapy: aspirin and 
clopidogrel (acetylsalicylic acid was obtained from Sigma 
Aldrich (A5376) whereas clopidogrel was extracted from 
Plavix (Sanofi) by Lodz University of Technology), 12 mg· 
kg-1 of body weight-1 · 24h-1 each (40 mice, 4T1+ASA-Cl). 
Drugs were pre-mixed with the standard chow diet and the 
food intake was monitored throughout the experiment. All 
mice were injected orthotopically with 1 × 104 4T1 murine 
breast cancer cells into one right thoracic mammary gland 
and received anti-platelet therapy starting from the 11th day 
after 4T1 cell injection, when the primary tumours were 
palpable in all mice. The anti-platelet therapy was continued 
until the end of the experiment. Animals were euthanized 
in the 5th terminal week of the disease. Animals from each 
group that died before their planned euthanasia were used 
to calculate survival in both groups. Intravenous injection: 
For the 24-hour model, 22 Balb/C mice were injected 
intravenously (i.v.) with 2×105 of 4T1-luc2td-Tomato 
cells following intraperitoneal injection (i.p.) of LPS at the 
dose of 1 mg · kg-1 of body weight 5 h before cancer cell 
inoculation. Aspirin and clopidogrel (both at a dose of 1 mg 
· kg-1 of body weight) were administered intravenously 45 
min before cancer cell inoculation (8 4T1+ASA/Cl mice) 
or saline (14 control 4T1 mice). The fluorescence of 4T1-
luc2td-Tomato cells in the lungs was measured 24 h after 
cancer cell injection using an in vivo MS FX PRO system 
(Carestream Health INC., USA). Images were analyzed 
with Carestream MI SE software (Carestream Health INC., 
USA). The intensity of the fluorescence signal is presented 
as the sum intensity of the region of interest and expressed in 
arbitrary units. For the 2-week model, 20 Balb/C mice were 
injected i.v. with 7.5×104 4T1-luc2td-Tomato cells following 
i.v. injection of platelet-depleting antibody at the dose of 
4 μg · g-1 of body weight (Emfret Analytics) (Ab mice) 15 
min before cancer cell inoculation. It was confirmed that the 
number of circulating platelets was reduced by 75% at that 
time (data not shown). Lung weight was measured and the 
number of pulmonary metastases was counted after mice 
euthanasia on the 13th day after 4T1 cell injection.
Cell culture
The mouse mammary adenocarcinoma 4T1 
cells were obtained from the American Type Culture 
Collection (ATCC, USA) and 4T1-luc2-tdTomato cell 
line stably expressing the firefly luciferase gene and 
tdTomato fluorescent protein was obtained from Caliper 
Life Sciences Inc. (USA). 4T1 cells were cultured in 
RPMI 1640-Glutamax medium (Sigma-Aldrich, Poland) 
supplemented with 10% fetal bovine serum (Gibco, Thermo 
Fisher Scientific, Poland), 1.0 mM sodium pyruvate (Sigma-
Aldrich, Poland) and antibiotic antimycotic solution (100 
units/mL penicillin and 100 μg/mL streptomycin, 25 μg/
mL amphotericin B) (Sigma-Aldrich, Poland). Cells were 
cultured at 37°C in a humidified atmosphere containing 
5% CO2. For inoculations, only 4T1 cells at the 2
nd passage 
were used. Prior to the transplantations, 4T1 cells were 
detached using Accutase solution (Sigma-Aldrich, Poland), 
centrifuged (300 g, 4°C, 5 min), counted, suspended in 
Hank’s Balanced Salt Solution (HBSS, IIET, Poland) at 
the appropriate count and inoculated into the mammary 
gland of female Balb/C mice or injected intravenously as 
described above. All cell cultures were routinely tested for 
Mycoplasma contamination.
Monitoring of primary tumour growth and 
pulmonary metastasis development
In the orthotopic model, the progression of 
breast cancer was monitored throughout the 5 weeks 
after inoculation of 4T1 breast cancer cells into the 
mammary fat pads of Balb/C mice by measuring 
their body weight and primary tumour volume with 
calipers once a week as described previously [46]. After 
euthanasia, primary tumours, lungs and spleens were 
excised, weighed and fixed in formalin for histological 
and immunohistochemical staining or frozen in liquid 
nitrogen for Western blot analysis. The number of 
pulmonary metastases was counted on lung lobes under 
the magnifying glass and on lung cross-sections stained 
with hematoxilin and eosin (H&E). Concomitantly, the 
relative metastatic area was measured and presented as 
the percentage of the cross-section area of the lung lobes. 
For 2-week intravenous model, body mass of mice was 
measured a week before 4T1 cell injection, at the time of 
injection and then once a week until mice were euthanized. 
After euthanasia, lungs were excised, weighed and fixed 
in formalin and the number of pulmonary metastases was 
counted on the lung lobes under the magnifying glass.
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Flow cytometry
Blood samples were collected on citrate from 
the right heart ventricle and processed as reported 
earlier [47]. The samples designated for flow cytometry 
measurements were diluted with saline, washed with 
Tyrode buffer and incubated with anti-mouse PE-
conjugated antibody directed against the active form 
of GPIIb/IIIa or P-selectin for determination of their 
platelet surface expression and anti-mouse FITC-labeled 
fibrinogen or von Willebrand (vWF) factor antibodies 
for determination of their binding on the platelet 
surface. Basal activation of circulating platelets and 
their ADP-dependent reactivity were evaluated on the 
basis of the measured expressions/binding of surface 
membrane antigens in samples supplemented with PBS 
or ADP to a final concentration of 20 μM, respectively. 
Platelets were identified by their forward- and side-
scatter characteristics and were gated on the basis of the 
expression of platelet-specific antigen CD41/61. Isotype 
matched FITC- or PE-conjugated control antibodies were 
used to assess non-specific binding. Flow cytometric 
analyses of platelet activation was performed using 
flow cytometry software (LSRII and FACS/Diva ver. 
6.0, respectively, Becton Dickinson, Oxford, UK). 
Measurements were made under a logarithmic gain 
and at least 10,000 events were collected. Appropriate 
colour compensation was determined in samples singly 
stained with either FITC-conjugated anti-CD41/61 or 
PE-conjugated anti-CD41/61. Unstained platelets were 
used to establish the level of autofluorescence that was 
set to fall within the first log order of brightness for each 
fluorescence channel. Suitable isotype controls were 
used as appropriate to set up the background noise at 
less than 1%. Events appearing above the background 
level were then recorded. Results were presented as the 
percentage of activation marker-positive events in the 
platelet population.
Ex vivo assay for TXB2 generation in stirred 
blood
Blood samples were diluted with saline (5 times) 
and stirred in alternating directions in 1ml cuvettes 
with disposable, siliconized stir bars (Chrono-Log, US) 
for one hour in 37°C (1500rpm; spinning time in one 
direction: 3s; acceleration/deceleration: 20000 rpm·s-1) 
in a specially-designed Xyzyk apparatus (Xyzyk Co, 
Poland), as described previously [48]. To determine basal 
and mechanically-stimulated ex vivo TXB2 generation in 
diluted blood, samples were taken on aspirin (500 μM) at 
the 2nd and 60th minute of ex vivo stirring of blood samples 
and centrifuged to obtain plasma (3000xg, 12 min, 4°C). 
TXB2 concentration in plasma was measured using an 
enzyme-linked immunosorbent assay ELISA kit (Enzo 
Life Sciences).
Western blotting
Platelets were isolated as described by [49]. 
Blood samples from mice were collected on 3.8 % 
sodium citrate. The samples were centrifuged at 100 G 
for 10 min to obtain PRP. Subsequently, platelets were 
pelleted at 600 G for 10 min. Platelet poor plasma (PPP) 
was discarded and the pellet containing platelets was 
suspended in Tyrode buffer and pelleted again at 600 G 
for 10 min. Subsequently, platelet pellet was put on ice 
and suspended in the lysis buffer containing protease 
and phosphatase inhibitors. Protein concentration was 
measured before sample pooling (BCA assay). Because of 
the limited protein content of platelet samples, the Western 
blot experiments were carried out on the pooled samples. 
The resting state of isolated platelets was confirmed 
by measuring their ADP-induced reactivity by flow 
cytometry. Lungs and primary tumours were homogenized 
for protein extraction with protease and phosphatase 
inhibitors. Protein concentration was measured with 
bicinchoninic acid assay (BCA assay). Subsequently, 
the samples from six mice in each experimental group 
were pooled together in such a way that an aliquots 
corresponding to equal amounts of protein from each 
sample were suspended in equal volumes for all mice in 
the group, in order to ensure equal representation of each 
individual sample in the pooled specimen. After addition 
of loading buffer, samples were heated at 96°C for 5 
min and then stored at -80°C. Equal amount of protein 
from each pooled sample was loaded and run on the gel, 
transferred to nitrocellulose or PVDF membrane, blocked 
with 5% dry milk and incubated with the appropriate 
primary antibodies directed against the following antigens: 
MMP-2 (ab19167), MMP-9 (ab19016), Ang-1 (ab8451), 
TSP-1 (ab85762), TGFβ1 (ab155264), VEGF(A) 
(ab68334), PDGF AB+BB (ab34074), vWF (ab9378), 
Slit2 (ab134166) were from Abcam, UK; MMP-14 was 
from Sigma Aldrich (sab4501901); Slpi (sc-374575), 
EphA1 (sc-377362), PGI2S (sc-20933) and VE-CAD (sc-
6458) were from Santa Cruz Biotechnology (TX, US); 
CD31 was from Novus Biologicals (NBP1-71663H); 
COX-2 was from Cayman Chemicals (aa584-598); eNOS 
was from BD Transduction Laboratories (610296); Ang-
2 was from Thermo Fisher Scientific (PA5-27297); PF4 
was from R&D Systems (AF595-SP); ROBO4 was from 
Biorbyt (orb101060). The appropriate HRP-conjugated 
secondary antibodies were from Santa Cruz Biotechnology 
(sc-2020, sc-2004 and sc-2005). For primary antibodies/
antigens producing ambiguous chemiluminescent signal, 
the experiments were repeated at least twice. Equal protein 
loading was controlled after electrophoresis and transfer 
for gels and membranes, respectively, using a stain free-
technique provided by Bio-Rad [50]. In case of primary 
tumours, the levels of selected antigens were probed not 
only on pooled samples but also on individual samples to 
confirm differences obtained in pooled samples.
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Histology
Spleens, lungs and primary tumours were fixed 
in formalin, paraffin-embeded and cut into 5 μm slices. 
Spleen cross-sections were stained with H&E and the 
number of megakaryocytes was counted for each mouse 
in ten random eyefield microphotographs of the spleen 
that were performed in such a way that the edge of the 
spleen was visible on each microphotograph, since most 
of the megakaryocytes resided in the spleen periphery. 
The mean number of megakaryocytes in one eyefield 
was counted for each mouse. Lung cross-sections were 
stained with H&E to count the number of metastatic foci 
and measure the relative metastasis area vs lung cross-
section area, as described above. Primary tumour cross-
sections were stained with H&E to assess the relative 
necrosis area, as reported by [51], and with combination 
of Periodic Acid Schiff staining (PAS) and anti-CD31 
(ab28364, Abcam, UK) to assess the number of PAS+/
CD31- pseudovessels and PAS+/CD31+ endothelium-
lined blood vessels, as reported previously [22]. All 
images were scanned with a BX51 microscope equipped 
with virtual microscopy system dotSlide (Olympus, 
Japan). Image segmentation was performed using Ilastik 
(developed by the Ilastik team, with partial financial 
support by the Heidelberg Collaboratory for Image 
Processing, HHMI Janelia Farm Research Campus and 
CellNetworks Excellence Cluster).
Measurement of blood cell count and nitrite, 
nitrate in plasma and HbNO in blood
The blood cell count was measured with an 
animal blood counter Vet abc (Horiba Medical, 
France). The samples designated for plasma extraction 
were centrifuged at 1000 x g/10 min/4 °C and plasma 
was aliquoted for measurement of NO2
- and NO3
-
 concentrations with ENO-20 NOx Analyzer (Eicom 
Corp., Kyoto, Japan). RBC were used for determination 
of nitrosylhemoglobin (HbNO) levels. The detection 
of HbNO was based on EPR spectra of the samples 
(erythrocytes obtained from whole blood by a 5 
min centrifugation at 1000 x g in 4 degrees Celsius) 
recorded in liquid nitrogen (77 K) using a Bruker 
EMX Plus spectrometer operating at X-band using a 
1041HS resonator. The following conditions were 
used: center field at G=2, microwave power 15.89 
mW; time constant of 81.92 ms; modulation frequency 
100 kHz; modulation amplitude 5 G; scan time 20.48 
s; scan width 200 G. For each sample, 30 individual 
scans were averaged. The level of microwave power 
has been determined from the power saturation curve 
to avoid saturation of the HbNO signal. For EPR 
signals values of amplitude of the second hyperfine 
line of nitrosylhemoglobin EPR spectra was used 
to calculate content of HbNO and the signal was 
normalized to sample weight and expressed in arbitrary 
units. The overlaying free radical signals at G = 2 were 
deconvoluted to enhance the HbNO signal assessment 
using an in-house algebraic process.
Statistical analysis
Data were presented as mean or median of the data 
without outliers (determined by Grubbs’ test) depending 
on data distribution (tested with D’Agostino test and 
Pearson omnibus normality test) and homogeneity of 
variances (tested with Brown-Forsythe’s test, F test or 
Barlett’s test). Some variable non-conforming with normal 
distribution and/or variance homogeneity were Box-Cox 
transformed and analysed with parametric tests, otherwise 
they were analysed with nonparametric inference tests. 
Only post-hoc P values < 0.05 were considered significant. 
The survival analysis was performed with the use of the 
Kaplan-Meier curves and the generalised Wilcoxon (Peto-
Prentice) test.
Abbreviations
ASA-aspirin, Cl-clopidogrel, VM-vascular mimicry, 
HbNO-nitrosylhemoglobin, H&E-haematoxilin and eosin 
staining, PAS- Periodic Acid Schiff staining.
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